Biotech Short Candidates Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Short Candidates

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (613)	12/1/2003 7:41:44 PM
From: Miljenko Zuanic	Read Replies (1) of 897

<< These were very sick patients, so the response they have gotten so far in this population doesn't seem bad at all. >> Well, who said so? I would like to know what were pts status (and genetic make up) at baseline, and what will be main criteria for PIII enrollment? "Avastin on market", is main driver for this "rush" toward RCC PIII trial. No activity at all(or minimal one), so far, in other indications. WHY? Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next